Desarrollo del test de inactivación de oncosferas para determinar la eficacia de la vacuna recombinante frente a la hidatidosis

Gertiser, María Laura; Poggio, Thelma Verónica.
Ciudad Autónoma de Buenos Aires; Argentina. Ministerio de Salud de la Nación. Dirección de Investigación en Salud; jul. 2016. 1-14 p. ilus, tab.
No convencional en Español | ARGMSAL, BINACIS | ID: biblio-1400285

Documentos relacionados

  1. Bias-interpretability Trade-offs in Vaccine Effectiveness Studies Using Test-negative or Cohort Designs.
  2. Global distribution of <i>Echinococcus granulosus</i> genotypes in domestic and wild canids: a systematic review and meta-analysis.
  3. Background risk should be taken into account when reporting vaccine effectiveness.
  4. Improving random forest predictions in small datasets from two-phase sampling designs.
  5. Discussion on "estimating vaccine efficacy over time after a randomized study is unblinded" by Anastasios A. Tsiatis and Marie Davidian.
  6. Rejoinder: Estimating vaccine efficacy over time after a randomized study is unblinded.
  7. Discussion on "Estimating vaccine efficacy over time after a randomized study is unblinded" by Anastasios A. Tsiatis and Marie Davidian.
  8. Discussion on "Estimating vaccine efficacy over time after a randomized study is unblinded" by Anastasios A. Tsiatis and Marie Davidian.
  9. Vaccine Effectiveness against Mpox in the United States.
  10. Vaccine Effectiveness against Mpox in the United States. Reply.